山東龍辰藥業(yè)有限公司(以下簡(jiǎn)稱龍辰)是蘇州美諾醫(yī)藥科技有限公司的子公司，于2020年12月在中國山東省鄒平市經(jīng)濟(jì)技術(shù)開發(fā)區(qū)醫(yī)藥產(chǎn)業(yè)園成立，總占地面積15萬平方米。
公司提供原料藥和藥品的早期發(fā)現(xiàn)、工藝開發(fā)、中試和cGMP生產(chǎn)一條龍服務(wù)，具備年產(chǎn)600噸原料藥的能力。主要產(chǎn)品包括(但不限于)硫辛酸(包括各種形式的硫辛酸)、右旋硫辛酸、釓布醇、噁拉戈利鈉等。第二階段目前正在建設(shè)中，預(yù)計(jì)2023年第一季度投產(chǎn)，生產(chǎn)更多原料藥、針劑、膠囊和片劑藥品。
As a subsidiary of Suzhou Medinoah Co., Ltd., Shandong Longzen Pharmaceutical Co., Ltd. (referred as Longzen in the following context) was established in December 2020 in the Pharmaceutical Industrial Park of Zouping Economic and Technology Development Zone, Shandong Province, China with a total area of 150k m2.
Longzen provides a one-stop service from early discovery, process development, pilot and cGMP production of APIs and drug products, with capabilities of annual production of 600 metric tons of APIs. The featured products include (but not limited to) Lipoic Acid (including various forms of lipoic acid), R-Lipoic Acid, Gadobutrol and Elagolix, etc. Phase II is currently under construction and expected to be launched by 2023/1Q with production of additional APIs and drug products of injectables, capsules and tablets.
